Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 3/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16148360 | 0.90 | SLC1A5 (0.53) | SLC1A5PTPN1GRIK1TAAR1NOS1 | |
| SCHEMBL16148359 | 0.90 | SLC1A5 (0.53) | SLC1A5PTPN1GRIK1TAAR1NOS1 | |
| SCHEMBL31691522 | 0.90 | SLC1A5 (0.53) | SLC1A5PTPN1GRIK1TAAR1NOS1 | |
| SCHEMBL22444963 | 0.90 | SLC1A5 (0.53) | SLC1A5PTPN1GRIK1TAAR1NOS1 | |
| SCHEMBL16542480 | 0.88 | SLC1A5 (0.45) | SLC1A5GRIK1NOS1POLBKMT2A | |
| SCHEMBL18522513 | 0.87 | TAAR1 (0.47) | SLC1A5PTPN1GRIK1TAAR1 | |
| SCHEMBL27254720 | 0.83 | SLC1A5 (0.48) | SLC1A5PTPN1TAAR1KMT2AKIF11 | |
| SCHEMBL431530 | 0.81 | DPP9 (0.44) | SLC1A5GRIK1NOS1GSR | |
| SCHEMBL16542500 | 0.81 | DPP9 (0.44) | SLC1A5GRIK1NOS1GSR | |
| SCHEMBL14381171 | 0.81 | SLC1A5 (0.51) | SLC1A5GRIK1TAAR1NOS1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919844-B2 | Antibacterials and/or modulators of biofilm formation and methods of using the same | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-02-16 | — | — | US | disclosed |
| US-20180215704-A1 | ANTIBACTERIALS AND/OR MODULATORS OF BIOFILM FORMATION AND METHODS OF USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-08-02 | — | — | US | disclosed |
| US-20170044097-A1 | ANTIBACTERIALS AND/OR MODULATORS OF BIOFILM FORMATION AND METHODS OF USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-02-16 | — | — | US | disclosed |
| US-8883963-B2 | Peptidomimetics with glucagon antagonistic and GLP 1 agonistic activities | CADILA HEALTHCARE LIMITED (IN) | 2014-11-11 | — | — | US | disclosed |
| EP-2231701-B1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP-1 AGONISTIC ACTIVITIES | CADILA HEALTHCARE LTD (IN) | 2012-04-18 | — | — | EP | disclosed |
| US-20120021972-A1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP 1 AGONISTIC ACTIVITIES | CADILA HEALTHCARE LIMITED (IN) | 2012-01-26 | — | — | US | disclosed |
| EP-2231701-A2 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP-1 AGONISTIC ACTIVITIES | Cadila Healthcare Limited (IN) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009125424-A2 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP-1 AGONISTIC ACTIVITIES | CADILA HEALTHCARE LIMITED (IN) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919844-B2 | Antibacterials and/or modulators of biofilm formation and methods of using the same | NRDC, FIBP, BMP2 | SLC1A5 3080/4885PTPN1 2564/4885GRIK1 3949/4885 |
| US-20180215704-A1 | ANTIBACTERIALS AND/OR MODULATORS OF BIOFILM FORMATION AND METHODS OF USING THE SAME | NRDC, FIBP, BMP2 | SLC1A5 3080/4885PTPN1 2564/4885GRIK1 3949/4885 |
| US-20170044097-A1 | ANTIBACTERIALS AND/OR MODULATORS OF BIOFILM FORMATION AND METHODS OF USING THE SAME | NRDC, FIBP, BMP2 | SLC1A5 3080/4885PTPN1 2564/4885GRIK1 3949/4885 |
| US-20120021972-A1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP 1 AGONISTIC ACTIVITIES | GLP1R, GPR119, GIPR | SLC1A5 1819/4885PTPN1 304/4885GRIK1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.